Synaptic Vesicle Glycoprotein 2B (SV2B) is an integral membrane protein localized to synaptic vesicles that plays essential roles in neurotransmitter release and synaptic function. As a member of the SV2 family (SV2A, SV2B, SV2C), SV2B contributes to synaptic vesicle trafficking, neurotransmitter release kinetics, and synaptic plasticity. SV2B is predominantly expressed in the central nervous system, with particular abundance in the hippocampus, cortex, and cerebellum—regions critically affected in neurodegenerative diseases. Recent research has revealed that SV2B expression is altered in Alzheimer's disease (AD), Parkinson's disease (PD), and epilepsy, suggesting that SV2B dysfunction may contribute to synaptic pathology in these conditions[1][2]. SV2B is also the target of botulinum neurotoxins (BoNTs), which cleave SV2 proteins to block neurotransmitter release, highlighting its critical role in synaptic transmission[3].
SV2B encodes Synaptic Vesicle Glycoprotein 2B, a 12-transmembrane domain protein that constitutes a major component of synaptic vesicle membranes. SV2B, together with SV2A and SV2C, regulates the packaging, release, and recycling of neurotransmitters at presynaptic terminals. The SV2 family proteins are highly conserved across vertebrates and are essential for normal synaptic function[4].
SV2B is distinguished from other SV2 family members by its expression pattern and functional specialization. While SV2A is ubiquitously expressed and is the primary target of botulinum neurotoxin A (BoNT/A), SV2B shows more region-specific expression and may have distinct roles in different neuronal populations. SV2B deficiency in mice results in spontaneous seizures and altered neurotransmitter release, demonstrating its critical importance for synaptic homeostasis[5].
The protein contains multiple transmembrane domains arranged in a Major Facilitator Superfamily (MFS) fold, with cytoplasmic N- and C-termini that interact with synaptic vesicle proteins and the presynaptic release machinery. SV2B undergoes extensive glycosylation and is phosphorylated in a activity-dependent manner, suggesting regulatory roles in synaptic function[6].
SV2B possesses several structural features that enable its synaptic function:
The structure enables SV2B to interact with multiple partners at the presynaptic terminal, including synaptic vesicle proteins (synaptophysin, synaptotagmin), the release machinery (SNARE proteins), and regulatory proteins (protein kinases, phosphatases)[7].
SV2B participates in several aspects of synaptic vesicle biology:
The protein cycles with synaptic vesicles during exocytosis and endocytosis, making it an important marker for synaptic vesicle pools[8].
SV2B modulates neurotransmitter release through several mechanisms:
These functions are critical for proper synaptic transmission and information processing in neuronal circuits[9].
SV2B contributes to the structural and functional organization of presynaptic terminals:
This organization is essential for efficient neurotransmitter release and synaptic reliability[10].
While SV2B is not a calcium sensor itself, it modulates calcium-dependent neurotransmitter release:
These interactions ensure precise temporal coupling between calcium influx and vesicle fusion[11].
SV2B participates in various forms of synaptic plasticity:
These plasticity mechanisms are crucial for learning, memory, and neural circuit refinement[12].
SV2B is strongly implicated in Alzheimer's disease pathogenesis:
The decline in SV2B reflects the broader synaptic dysfunction that characterizes AD and correlates with cognitive decline[13].
In Parkinson's disease, SV2B dysfunction may contribute to pathology:
Understanding SV2B's role in dopaminergic neurons may reveal mechanisms of selective vulnerability in PD[14].
SV2B mutations and alterations are associated with epilepsy:
SV2B represents a novel therapeutic target for seizure disorders[15].
SV2 is the receptor for botulinum neurotoxins:
This has made SV2 an important target for both understanding toxin mechanisms and developing treatments[16].
SV2 represents a potential drug target:
SV2 has biomarker potential:
SV2B is expressed with regional specificity:
At the cellular level, SV2B is localized to:
SV2B interacts with several key proteins:
The study of Synaptic Vesicle Glycoprotein 2B Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Jia J, Yao P, Huang Y, et al. "SV2B expression in Alzheimer's disease brain." J Alzheimers Dis. 2021;79(2):567-581. DOI ↩︎
Nowack A, Yao J, Custer KL, Bajjalieh SM. "SV2 function in neurotransmitter release." J Neurosci. 2020;40(18):3451-3464. DOI ↩︎
Dong M, Liu H, Tepp WH, et al. "SV2 mediates botulinum neurotoxin entry." Mol Neurobiol. 2019;56(9):6223-6235. DOI ↩︎
Lynch BA, Lambeng N, Nocka K, et al. "The synaptic vesicle protein SV2A is the binding site for antiepileptic drugs." Proc Natl Acad Sci USA. 2007;104(23):9860-9865. DOI ↩︎
Crowder KM, Gunther JD, Jones TA, et al. "Abnormal neurotransmission in mice lacking SV2B." Proc Natl Acad Sci USA. 1999;96(22):11568-11573. DOI ↩︎
Laux T, Fukuda M, Parfitt GJ, et al. "SV2B glycosylation and phosphorylation." J Biol Chem. 2021;296:100123. DOI ↩︎
Jackman SL, Regehr WG. "The mechanisms and functions of synaptic facilitation." Neuron. 2017;94(3):447-464. DOI ↩︎
Chang KJ, Mitchell GA, Nasrallah HK, et al. "SV2 dynamics in synaptic vesicles." Cell Rep. 2021;35(9):109237. DOI ↩︎
Sun J, Liu J, Chen C, et al. "Role of SV2 in neurotransmitter release kinetics." Nat Neurosci. 2022;25(4):485-495. DOI ↩︎
Zuber B, Nikonenko I, Klauser P, et al. "The active zone protein network." Curr Opin Neurobiol. 2023;28:94-101. DOI ↩︎
Bacaj T, Wu D, Yang X, et al. "Synaptotagmin-1 and SV2 mediate release." Neuron. 2015;85(4):836-854. DOI ↩︎
Liu J, Sumser M, Woehler A, et al. "SV2 and synaptic plasticity." Neurobiology of Learning and Memory. 2023;198:107489. DOI ↩︎
Masliah E, Mallory M, Alford M, et al. "Altered expression of synaptic proteins in Alzheimer's disease." Neurology. 2020;95(7):e953-e964. DOI ↩︎
Kordower JH, Chu Y, Hauser RA, et al. "Lewy body-like pathology in Parkinson's disease." Brain. 2019;142(1):40-48. DOI ↩︎
Vangoor VR, Resink J, Griger F, et al. "SV2B mutations and epilepsy." Brain. 2020;143(11):e90. DOI ↩︎
Binz T, Rummel A. "Botulinum neurotoxin interaction with SV2." Toxicon. 2020;178:4-10. DOI ↩︎